EP3227686 - MULTIPLEXED IMMUNOHISTOCHEMISTRY ASSAYS FOR DIAGNOSIS AND TREATMENT OF CANCER [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 26.06.2020 Database last updated on 31.08.2024 | |
Former | Examination is in progress Status updated on 04.06.2019 | ||
Former | Request for examination was made Status updated on 08.09.2017 | ||
Former | The international publication has been made Status updated on 30.06.2017 | Most recent event Tooltip | 26.06.2020 | Application deemed to be withdrawn | published on 29.07.2020 [2020/31] | Applicant(s) | For all designated states Ignyta, Inc. 11111 Flintkote Avenue San Diego, CA 92121 / US | [2017/41] | Inventor(s) | 01 /
CHRISTIANSEN, Jason, Hans 371D Pine Avenue Carlsbad, CA 92008 / US | 02 /
MURPHY, Danielle, Anthea 752 Stevens Avenue Solana Beach, CA 92075 / US | 03 /
BOOMER, Aaron, Scott 743 Sunset Drive Vista, CA 92081 / US | 04 /
LAMOUREUX, Jennifer, Lyn 353 Aspen Creek Way Oceanside, CA 92057 / US | [2017/41] | Representative(s) | HGF HGF Limited 1 City Walk Leeds LS11 9DX / GB | [N/P] |
Former [2017/41] | HGF Limited 4th Floor Merchant Exchange 17-19 Whitworth Street West Manchester M1 5WG / GB | Application number, filing date | 15864500.2 | 01.12.2015 | [2017/41] | WO2015US63163 | Priority number, date | US201462086921P | 03.12.2014 Original published format: US 201462086921 P | [2017/41] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2016089853 | Date: | 09.06.2016 | Language: | EN | [2016/23] | Type: | A1 Application with search report | No.: | EP3227686 | Date: | 11.10.2017 | Language: | EN | The application published by WIPO in one of the EPO official languages on 09.06.2016 takes the place of the publication of the European patent application. | [2017/41] | Search report(s) | International search report - published on: | US | 09.06.2016 | (Supplementary) European search report - dispatched on: | EP | 26.07.2018 | Classification | IPC: | G01N33/574, A61P35/00, A61K31/496, C12Q1/6813, C12Q1/686, G01N27/447 | [2018/35] | CPC: |
G01N33/57484 (EP,US);
A61K31/496 (EP,US);
A61P35/00 (EP);
C12Q1/6813 (US);
C12Q1/686 (US);
G01N27/447 (US);
G01N33/57411 (US);
G01N33/57415 (US);
G01N33/57423 (US);
G01N33/57449 (US);
G01N2800/52 (EP,US);
G01N2800/7028 (US);
G01N33/57438 (EP,US)
(-)
|
Former IPC [2017/41] | G01N33/574, A61P35/00, A61K31/496 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2017/41] | Title | German: | MULTIPLEXIERTE IMMUNHISTOCHEMIE-ASSAYS ZUR DIAGNOSE UND BEHANDLUNG VON KREBS | [2017/41] | English: | MULTIPLEXED IMMUNOHISTOCHEMISTRY ASSAYS FOR DIAGNOSIS AND TREATMENT OF CANCER | [2017/41] | French: | ANALYSES D'IMMUNOCYTOCHIMIE MULTIPLEXÉES POUR LE DIAGNOSTIC ET LE TRAITEMENT D'UN CANCER | [2017/41] | Entry into regional phase | 29.06.2017 | National basic fee paid | 29.06.2017 | Search fee paid | 29.06.2017 | Designation fee(s) paid | 29.06.2017 | Examination fee paid | Examination procedure | 29.06.2017 | Examination requested [2017/41] | 29.06.2017 | Date on which the examining division has become responsible | 25.02.2019 | Amendment by applicant (claims and/or description) | 07.06.2019 | Despatch of a communication from the examining division (Time limit: M06) | 18.12.2019 | Application deemed to be withdrawn, date of legal effect [2020/31] | 24.01.2020 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time [2020/31] | Fees paid | Renewal fee | 21.12.2017 | Renewal fee patent year 03 | 19.12.2018 | Renewal fee patent year 04 | 10.12.2019 | Renewal fee patent year 05 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [XY]WO2009013126 (NERVIANO MEDICAL SCIENCES SRL [IT], et al) [X] 1-3,5-14 * page 5 * * page 19, lines 1-2 * * page 85, line 15 - page 86, line 6 * * page 13, lines 19-20; compound 11 * * page 22, lines 5-7 * * pages 75,99 * [Y] 15; | [XP]WO2015124697 (IGNYTA INC [US], et al) [XP] 1-3,5-15 * paragraphs [0036] , [0040] - [0043] * * page 41, paragraphs 248,249 *; | [E]WO2016089760 (IGNYTA INC [US]) [E] 1-3,5-15 * paragraphs [0011] , [0014] - [0016] * * paragraphs [0063] - [0065] *; | [Y]WO2012019132 (CELL SIGNALING TECHNOLOGY INC [US], et al) [Y] 15 * paragraphs [0009] , [0013] , [0022] , [0 27] *; | [XP]WO2015157624 (SLOAN KETTERING INST CANCER [US]) [XP] 1,3,5,7-11,14 * page 2, lines 1-21 * * page 5, line 26 - page 6, line 18 * * page 7, line 21 - page 8, line 25 * * pages 7,32 *; | [XI] - Elena Ardini ET AL, "A highly potent, selective and orally available ALK inhibitor with demonstrated antitumor efficacy in ALK dependent lymphoma and non small cell lung cancer models | Cancer Research", Proc Am Assoc Cancer Res; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009, (20090418), page Abstract #3737, URL: http://cancerres.aacrjournals.org/content/69/9_Supplement/3737, (20180711), XP055491721 [X] 1,3,6,10-13,15 * abstract * [I] 5,7-9,14 | [XI] - Ardini Ardini ET AL, "Characterization of NMS-E628, a small molecule inhibitor of anaplastic lymphoma kinase with antitumor efficacy in ALK-dependent lymphoma and non-small cell lung cancer models | Molecular Cancer Therapeutics", Mol Cancer Ther 2009;8(12 Suppl):A244., (20091115), page Abstract A243, URL: http://mct.aacrjournals.org/content/8/12_Supplement/A244, (20180711), XP055491735 [X] 1,3,6,10-13,15 * abstract * [I] 5,7-9,14 | [XI] - Elena Ardini ET AL, "In vitro and in vivo activity of NMS-E628 against ALK mutations resistant to Xalkori. | Molecular Cancer Therapeutics", Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics: AACR; Mol Cancer Ther 2011;10(11 Suppl):Abstract nr A232, (20111112), page Abstract A232, URL: http://mct.aacrjournals.org/content/10/11_Supplement/A232, (20180711), XP055491739 [X] 1,3,10,11,14,15 * abstract * [I] 9 | [XI] - Elena Ardini ET AL, "The ALK inhibitor NMS-E628 also potently inhibits ROS1 and induces tumor regression in ROS-driven models.", Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 2092, (20130406), page Abstract 2092, URL: http://cancerres.aacrjournals.org/content/73/8_Supplement/2092, (20180711), XP055491741 [X] 1,3,6,10-15 * abstract * [I] 5,7-9 | [XI] - Filippo G De Braud ET AL, "Phase 1 open label, dose escalation study of RXDX101, an oral pan-trk, ROS1, and ALK inhibitor, in patients with advanced solid tumors with relevant molecular alterations.: Journal of Clinical Oncology: Vol 32, No 15_suppl", ournal of Clinical Oncology 32, no. 15_suppl (May 20 2014) 2502-2502, (20140520), URL: http://ascopubs.org/doi/abs/10.1200/jco.2014.32.15_suppl.2502, (20180711), XP055491745 [X] 1,3,6,14,15 * abstract * [I] 5,7-13 | [XI] - ARDINI E ET AL, "NMS-E628, a potent and orally available small molecule inhibitor of anaplastic lymphoma kinase, reduces tumor growth in an intracranial model of ALK-dependent NSCLC", EUROPEAN JOURNAL OF CANCER. SUPPLEMENT, PERGAMON, OXFORD, GB, vol. 8, no. 7, doi:10.1016/S1359-6349(10)71875-9, ISSN 1359-6349, (20101101), page 59, (20101101), XP027497858 [X] 1,3,6,14,15 * abstract * [I] 5,7-13 DOI: http://dx.doi.org/10.1016/S1359-6349(10)71875-9 | [XI] - David Anderson ET AL, "Inhibition of Trk-driven tumors by the pan-Trk inhibitor RXDX-10", EORTC-NCI-AACR 2014, (20141101), page abstract 310, URL: https://ignyta.com/wp-content/uploads/2016/10/Anderson-et-al_EORTC-2014.pdf.pdf, (20180711), XP055491752 [X] 1,3,5-7,10-15 * abstract * [I] 8,9 | International search | [Y]WO2014046730 (VENTANA MED SYST INC [US]) [Y] 1-32 * ; page 2, lines 1-20; page 5, lines 1-10; page 8, lines 1-6; page 11, lines,15-35; page 12, lines 1-15; page 18, lines 29-33; page 19, lines 1-35 *; | [Y]WO2013174876 (NERVIANO MEDICAL SCIENCES SRL [IT]) [Y] 1-32 * ; page 1 paragraph 1, page 2 paragraph 3 *; | [Y]US2013303461 (IAFRATE ANTHONY JOHN [US], et al) [Y] 6, 23/6 * ; paragraphs [0017]-[0019] * |